Hologic shares undervalued – Needham & Company
Hologic (HOLX) shares undervalued – Needham & Company
HOLX
+1.31%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
Needham & Company upgraded shares of Hologic (NASDAQ:HOLX) to Buy from Hold, assigning a price target of $95 per share in a note Friday.
Analysts told investors that easing Covid testing headwinds will unmask growth drivers for the company.
“We think the COVID-related headwind will soon end and that HOLX can grow at least at its 5-7% organic ex-COVID growth target,” they explained.
“Additionally, we foresee potential for above-normal non-COVID Diagnostics, Breast Health, and GYN Surgical growth in the next few quarters. We also believe that HOLX can drive ~50+ bps of annual operating margin improvement and 8-12% EPS growth,” they added.
The analysts concluded that based on the growth profile and HOLX’s P/E of 20.2x, Needham’s CY2023 estimate, they believe that the company’s shares are undervalued.
